Endothelin Receptor Antagonists: all 328 studies that test it

Page 1 of 4. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.

• A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingNCT07850752Phase 3
• Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)Not yet recruitingNCT07820995Phase 4
• A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionNot yet recruitingNCT07635914Phase 3
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 3
• Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive AnginaRecruitingNCT07392281Early Phase 1
• COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesRecruitingNCT07245680Phase 3
• Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated ProteinuriaRecruitingNCT07224776Phase 1
• Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionNot yet recruitingNCT06987097Not applicable
• Comparison of Sequential to Initial Combination Therapy in PAHRecruitingNCT06968962Not applicable
• Bosentan in the Treatment of Giant Cell ArteritisNot yet recruitingNCT06957002Phase 2
• Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)RecruitingNCT06887062Phase 2
• A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with ProteinuriaRecruitingNCT06819826Phase 3
• Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)RecruitingNCT06811831Early Phase 1
• Efficacy of Endothelin Receptor Antagonism in Coronary Artery SpasmEnrolling by invitationNCT06432452Phase 2/3
• dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized EvaluationNot yet recruitingNCT06072326Phase 2
• A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingNCT05179876Phase 3
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingNCT05003986Phase 2
• Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial HypertensionRecruitingNCT04972656Not applicable
• A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyRecruitingNCT04663204Phase 2
• Endothelin-1 Receptor Blockade in Resistant HypertensionRecruitingNCT04388124Phase 2
• : Vascular Function in Health and DiseaseRecruitingNCT02966665Phase 1
• ENDOTHELION Study Group: Effect of Bosentan in NAION PatientsRecruitingNCT02377271Phase 3
• A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCKCompletedNCT06269484Phase 2Results posted
• A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANCompletedNCT05856760Phase 2Results posted
• Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedNCT05834738Phase 2Results posted
• A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the BloodCompletedNCT05723874Phase 1Results posted
• Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)TerminatedNCT05516498Phase 2Results posted
• Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)CompletedNCT05373108Phase 4Results posted
• A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial HypertensionCompletedNCT05167825Phase 3Results posted
• Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid TumorsCompletedNCT05072106Phase 1Results posted
• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)CompletedNCT04724837Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary HypertensionTerminatedNCT04271475Phase 3Results posted
• An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.TerminatedNCT03775421Phase 3Results posted
• A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyCompletedNCT03762850Phase 3Results posted
• A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular DiseaseTerminatedNCT03714815Phase 2Results posted
• Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the BrainCompletedNCT03585270Phase 3Results posted
• A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its SafetyCompletedNCT03541174Phase 3Results posted
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT03493685Phase 3Results posted
• Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated SubjectsCompletedNCT03153137Phase 3Results posted
• A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular DiseaseCompletedNCT03153111Phase 2Results posted
• A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)CompletedNCT02932410Phase 3Results posted
• Crossover Study From Macitentan or Bosentan Over to AmbrisentanTerminatedNCT02885012Phase 4Results posted
• Influence of Bosentan on the Pharmacokinetics of NintedanibCompletedNCT02667704Phase 1Results posted
• Macitentan in Pulmonary Hypertension of Sickle Cell DiseaseTerminatedNCT02651272Phase 2Results posted
• Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential HypertensionCompletedNCT02603809Phase 2Results posted
• Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device ImplantationCompletedNCT02554903Phase 2Results posted
• PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical TrialCompletedNCT02382016Phase 4Results posted
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtensionCompletedNCT02310672Phase 4Results posted
• Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)CompletedNCT02290613Phase 2Results posted
• The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension StudyTerminatedNCT02253394Phase 4Results posted
• Contribution of Endothelin-1 to Exercise Intolerance in Heart FailureCompletedNCT02124824Early Phase 1Results posted
• Atrasentan Spermatogenesis and Testicular FunctionCompletedNCT02118714Phase 2Results posted
• A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and SpainTerminatedNCT02081690Phase 3Results posted
• Ambrisentan in Single VentricleCompletedNCT02080637Phase 2Results posted
• Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular DysfunctionCompletedNCT02070991Phase 2Results posted
• Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionCompletedNCT02060721Phase 2Results posted
• Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionCompletedNCT02021292Phase 2Results posted
• The Effects of Ambrisentan on Exercise Capacity in Fontan PatientsCompletedNCT01971580Phase 4Results posted
• Drug Combination on Exercise Performance at High AltitudeCompletedNCT01902758Phase 2/3Results posted
• A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)TerminatedNCT01894022Phase 3Results posted
• Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.TerminatedNCT01884675Phase 3Results posted
• Study Of Diabetic Nephropathy With AtrasentanTerminatedNCT01858532Phase 3Results posted
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT InstrumentTerminatedNCT01847014Phase 3Results posted
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT InstrumentCompletedNCT01841762Phase 3Results posted
• Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT01808313Phase 3Results posted
• Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger SyndromeCompletedNCT01743001Phase 3Results posted
• Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger SyndromeTerminatedNCT01739400Phase 3Results posted
• Bosentan and Pulmonary Endothelial FunctionCompletedNCT01721564Not applicableResults posted
• Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisCompletedNCT01613118Phase 2Results posted
• The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy VolunteersCompletedNCT01530464Phase 1Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsTerminatedNCT01474122Phase 3Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsCompletedNCT01474109Phase 3Results posted
• Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension ParticipantsCompletedNCT01392469Phase 3Results posted
• Persistent Pulmonary Hypertension of the NewbornTerminatedNCT01389856Phase 3Results posted
• Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529CompletedNCT01342952Phase 2Results posted
• An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)CompletedNCT01338636Phase 4Results posted
• FUTURE 3 Study ExtensionCompletedNCT01338415Phase 3Results posted
• Safely Change From Bosentan to Ambrisentan in Pulmonary HypertensionCompletedNCT01330108Phase 4Results posted
• A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesTerminatedNCT01244620Phase 1Results posted
• Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label TrialCompletedNCT01224210Phase 3Results posted
• Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial HypertensionCompletedNCT01223352Phase 3Results posted
• Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsTerminatedNCT01210443Phase 3Results posted
• A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsTerminatedNCT01204853Phase 3Results posted
• A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT01178073Phase 3Results posted
• ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate CancerTerminatedNCT01119118Phase 2Results posted
• Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic SclerosisCompletedNCT01093885Not applicableResults posted
• Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or FeetCompletedNCT01072669Not applicableResults posted
• Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With AmbrisentanCompletedNCT01051960Phase 4Results posted
• Endothelin Blockade in Patients With Single Ventricle PhysiologyCompletedNCT00989911Not applicableResults posted
• ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian CancerTerminatedNCT00929162Phase 2Results posted
• Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical StudyCompletedNCT00903331Phase 2Results posted
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00879229Phase 3Results posted
• Safety and Efficacy Trial to Treat Diastolic Heart Failure Using AmbrisentanTerminatedNCT00840463Phase 4Results posted
• Confirming The Sitaxsentan Dose In Patients Undergoing Heart SurgeryCompletedNCT00838383Phase 2Results posted
• Insulin Resistance in Pulmonary Arterial HypertensionTerminatedNCT00825266Phase 2Results posted
• Bosentan for Poorly Controlled AsthmaTerminatedNCT00815347Phase 2Results posted
• A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial HypertensionTerminatedNCT00811018Phase 3Results posted
• Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease SubjectsCompletedNCT00810732Phase 2Results posted
• Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding SildenafilTerminatedNCT00796666Phase 3Results posted
• Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term SafetyTerminatedNCT00796510Phase 3Results posted

← Endothelin Receptor Antagonists overview